Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9646398 | 1.00 | PPARG (0.47) | PPARGCSNK1EPPARARECQLCYSLTR2 | |
| SCHEMBL8499483 | 1.00 | PPARG (0.47) | PPARGCSNK1EPPARARECQLCYSLTR2 | |
| SCHEMBL10060891 | 0.98 | PPARG (0.45) | PPARGCSNK1EPPARARECQLCYSLTR2 | |
| SCHEMBL15094197 | 0.93 | ALDH1A1 (0.41) | PPARGCSNK1ERECQLMEN1KMT2A | |
| SCHEMBL6741649 | 0.87 | HTT (0.40) | PPARGMEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL6684572 | 0.87 | HTT (0.40) | PPARGMEN1KMT2ASLC18A3SIGMAR1 | |
| SCHEMBL23169058 | 0.84 | CYSLTR2 (0.47) | PPARGCSNK1ERECQLCYSLTR2CYSLTR1 | |
| SCHEMBL22358954 | 0.84 | CYSLTR2 (0.47) | PPARGCSNK1ERECQLCYSLTR2CYSLTR1 | |
| SCHEMBL23190512 | 0.82 | RECQL (0.43) | PPARGCSNK1ERECQLCYSLTR2CYSLTR1 | |
| SCHEMBL31357687 | 0.81 | SLC18A3 (0.39) | PPARGSLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499604-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003093257-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | PPARG 26/4885CSNK1E 2228/4885PPARA 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.